MEDICINOVA, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $409.7K | — | $1.0M | — | $4.0M | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $6.7M | $6.8M | $5.3M | $8.7M | $8.1M | $7.1M | $5.7M |
| SG&A Expense | — | $6.2M | $5.5M | $5.2M | $5.5M | $5.7M | $6.7M | $8.0M |
| Operating Income | — | $-13.3M | $-12.7M | $-9.9M | $-14.6M | $-10.2M | $-14.2M | $-14.0M |
| Operating Margin | — | -3,242.5% | — | -990.0% | — | -253.0% | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-12.0M | $-11.0M | $-8.6M | $-14.1M | $-10.1M | $-13.9M | $-12.9M |
| Income Tax Expense | — | $6.0K | $5.5K | $3.0K | $2.8K | $2.6K | $-1.6K | $12.7K |
| Net Income | — | $-12.0M | $-11.0M | $-8.6M | $-14.1M | $-10.1M | $-13.9M | $-12.9M |
| Net Margin | — | -2,928.8% | — | -857.2% | — | -251.0% | — | — |
| EPS (Basic) | — | $-0.24 | $-0.23 | $-0.17 | $-0.29 | $-0.21 | $-0.31 | $-0.30 |
| EPS (Diluted) | — | $-0.24 | $-0.23 | $-0.17 | $-0.29 | $-0.21 | $-0.31 | $-0.30 |
| Shares Outstanding (Basic) | 49.2M | 49.1M | 49.0M | 49.0M | 49.0M | 48.6M | 45.0M | 43.9M |
| Shares Outstanding (Diluted) | 49.2M | 49.1M | 49.0M | 49.0M | 49.0M | 48.6M | 45.0M | 43.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |